BOSUTINIB MONOHYDRATE |
BOSULIF |
SKI-606 |
SK-606 |
BOSUTINIB |
SKI 606 |
BOSUTINIBUM |
SK 606 |
4-((2,4-DICHLORO-5-METHOXYPHENYL)AMINO)-6-METHOXY-7-(3-(4-METHYL-1-PIPERAZINYL)PROPOXY)-3-QUINOLINECARBONITRILE |
4-((2,4-DICHLORO-5-METHOXYPHENYL)AMINO)-6-METHOXY-7-(3-(4-METHYLPIPERAZIN-1-YL)PROPOXY)QUINOLINE-3-CARBONITRILE |
3-QUINOLINECARBONITRILE, 4-((2,4-DICHLORO-5-METHOXYPHENYL)AMINO)-6-METHYL-1-PIPERAZINYL)PROPOXY)- |
BOSULIF® |
chemidplus:380843-75-4 |
pubchem.compound:5328940 |
drugbank:06616 |
chembl:CHEMBL288441 |
rxcui:1307619 |
FDA Approval | Chronic myelogenous leukemia (Philadelphia chromosome positive) |
Drug Class | Kinase Inhibitors |
FDA Approval | not approved |
Drug Class | Small molecule |
Drug Indications | antineoplastic agent |
Drug Categories | cytochrome p-450 cyp2c8 inhibitors |
Drug Categories | cytochrome p-450 cyp2c8 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a inhibitors |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | immunosuppressive agents |
Drug Categories | kinase inhibitor |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | p-glycoprotein substrates |
Drug Categories | p-glycoprotein substrates with narrow therapeutic index |
Drug Categories | tyrosine kinase inhibitors |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Variant Effect | gain-of-function |
Pathway | activation |
Clinical Status | NCCN guidelines |
inhibitor (inhibitory) |
Specific Action of the Ligand | None |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Tyrosine-protein kinase HCK inhibitor |
inhibitor (inhibitory) |
Mechanism of Interaction | Tyrosine-protein kinase Lyn inhibitor |
Direct Interaction | yes |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
BOSUTINIB | DrugBank Drug Name |
380843-75-4 | CAS Number |
Bosulif | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Categories | amines |
SKI-606 | Development Name |
BOSUTINIB | Generic Name |
BOSULIF | Trade Name |
Drug Class | Kinase Inhibitors |
FDA Approval | Chronic myelogenous leukemia (Philadelphia chromosome positive) |
Drug Indications | antineoplastic agent |
Drug Class | Small molecule |
FDA Approval | not approved |
BOSUTINIB | Primary Drug Name |
BOSUTINIB | Drug Generic Name |
SKI-606 | Drug Synonym |
BOSUTINIB | GuideToPharmacology Ligand Name |
D0OB0F | TTD Drug ID |